AnalystBook Research · Company Intelligence

BlueLinx Holdings Inc.

BXCNYSE

Built from BlueLinx Holdings Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

BlueLinx reported $2.95B of FY2026 revenue in the local extract, with thin net income, positive FCF, and a specialty-products-led mix.

The read at a glance✓ Audited against SEC data
  • Business mixBuilding-products distributionNote
  • Revenue$2.95B, flat in local rowNote
  • Net income$0.2MWatch
  • FCF$32.9MOK
  • Buybacks$38.1MNote
  • Insiders0 purchases / 0 salesNote
  • AccountingAltman grey; EQ safeOK

Business

BlueLinx is a U.S. two-step wholesale distributor of residential and commercial building products.

Where the revenue comes from

Fiscal 2025, as BlueLinx Holdings Inc. reports it. History and quarterly detail are in the app.

  • Specialty products$2.1B
  • Structural products$901.0M

Leadership changes

From BlueLinx Holdings Inc.'s own filings, the day they're filed.

  • Michael Wilson · Chief Commercial Officer · departureeff. 2026-08-01
  • Kimberly A. DeBrock · President · appointmenteff. 2023-09-29
  • R. Andrew Wamser Jr · departure

Latest filings

  • 8-K · Company announcement2026-08-04
  • 10-Q · Quarterly report2026-08-04
  • 8-K · Company announcement2026-05-19
  • 8-K · Company announcement2026-05-05
  • 10-Q · Quarterly report2026-05-05
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about BlueLinx Holdings Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.